Once a new drug is developed, there is a rush to get it to the market to help as many as possible. Patients who are very ill who might benefit from the new drug are quick to request access to it. But time is telling us that:
- Rushing drugs through approvals isn't necessarily the best idea. The side effects and additional issues caused to patients actually cause more cost to the health care system and do not necessarily help the patients.
- The drug developers are supposed to continue their research but do not always comply.
- The FDA is not equipped to monitor the drug developers and review their additional study results.